Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
XRCC3	7517	CARBOQUONE	CHEMBL443014		PharmGKB
XRCC3	7517	DOCETAXEL	CHEMBL92		PharmGKB
XRCC3	7517	FLUOROURACIL	CHEMBL185		PharmGKB

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
XRCC3	rs861539	A	Platinum compounds	efficacy	not stated		Allele A is not associated with response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	23940523	1184511758
XRCC3	rs861539	A	Platinum compounds	efficacy	not stated		Allele A is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.	23940523	1184511789
XRCC3	rs861539	AA	cisplatin	efficacy	yes	Response was "time to progression" and length of survival.	Genotype AA is associated with decreased response to cisplatin, docetaxel and irinotecan in people with Stomach Neoplasms as compared to genotypes AG + GG.	18335219	1184985954
XRCC3	rs861539	AA + AG	Platinum compounds	efficacy	yes	"CC genotype of XRCC3 C18067T carriers showed more resistance to platinum-based chemotherapy when compared to those with CT or TT genotypes."	Genotypes AA + AG are associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	27248474	1448123636